CancerNetwork® shares its latest investigation into novel practices for rendering surgical management of prostate cancer from experts at Vanderbilt Institute for Surgery and Engineering.
CancerNetwork® analyzed the development of a minuscule robot from investigators at the Vanderbilt Institute for Surgery and Engineering that has the potential to revolutionize surgical procedures for treating prostate cancer. Using a lifelike model, the team demonstrated that the device could remove prostate glands and tissues through the urethra as well as accomplish the difficult step of suturing the bladder to the urethra.
Duke Herrell III, a professor of urology and biomedical and mechanical engineering, providesd key insights into the development of the technology and what it means for the future of prostate cancer maintenance in this episode of Inside the Practice.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.